Nabriva Therapeutics AG Insiders
Nabriva Therapeutics employs about 39 people. The company is managed by 9 executives with a total tenure of roughly 16 years, averaging almost 1.0 years of service per executive, having 4.33 employees per reported executive. Recap of Nabriva Therapeutics' management performance can provide insight into the venture performance.
| Theodore Schroeder CEO CEO Director |
Nabriva |
Nabriva Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.652) % which means that it has lost $0.652 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6853) %, meaning that it created substantial loss on money invested by shareholders. Nabriva Therapeutics' management efficiency ratios could be used to measure how well Nabriva Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Nabriva Therapeutics Workforce Comparison
Nabriva Therapeutics AG is regarded second in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 377. Nabriva Therapeutics retains roughly 39.0 in number of employees claiming about 10% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.48) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.29) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.29. Nabriva Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nabriva Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nabriva Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Nabriva Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
George Talbot over a year ago Exercise or conversion by George Talbot of 155 shares of Nabriva Therapeutics subject to Rule 16b-3 | ||
Theodore Schroeder over a year ago Payment of 431 shares by Theodore Schroeder of Nabriva Therapeutics subject to Rule 16b-3 |
Nabriva Therapeutics Notable Stakeholders
A Nabriva Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nabriva Therapeutics often face trade-offs trying to please all of them. Nabriva Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nabriva Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Colin MD | CEO and Member of Management Board | Profile | |
| Theodore Schroeder | CEO Director | Profile | |
| Gary Sender | Consultant | Profile | |
| BA Esq | G Sec | Profile | |
| Daniel Dolan | Chief Officer | Profile | |
| Steven D | Chief Devel. Officer and Member of Management Board | Profile | |
| Jodi VanDerveer | VP HR | Profile | |
| Werner Heilmayer | VP IP | Profile | |
| MBA MD | Chief Officer | Profile |
Nabriva Therapeutics Workforce Analysis
Traditionally, organizations such as Nabriva Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nabriva Therapeutics within its industry.Nabriva Therapeutics Manpower Efficiency
Return on Nabriva Therapeutics Manpower
| Revenue Per Employee | 914.6K | |
| Revenue Per Executive | 4M | |
| Net Loss Per Employee | 1.5M | |
| Net Loss Per Executive | 6.4M | |
| Working Capital Per Employee | 89.7K | |
| Working Capital Per Executive | 388.8K |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |